Dr Allen Bollands. Cynata CEO agreed. “Cynata’s cellular platform is based upon pluripotent stems cells and has a number of characteristics which make it very attractive as a therapeutic agent. Not the least of these is the potential to make massive quantities of uniform, well characterized, pharmaceutical grade cells in a cost effective manner”, he said. “However, clearly, we also need to know that the cells have therapeutic affect as well. These results give us great confidence to press on with our development programme.”
ECQ Price at posting:
2.2¢ Sentiment: Buy Disclosure: Held
